According to GlobalData, URSA is one of 67 product lines sold in the US cardiac catheters market; these product lines are sold by 17 different manufacturers. The price of the URSA device can be viewed in GlobalData’s micro pricing report and can be retrieved according to purchase date, facility type, bed size, and geographical region. Buy the report here.
The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches.
In addition, the final selling pricing of medical devices is also impacted by the discounting policy of the manufacturer. Companies such as Tristate URSA apply discounts for their devices based on their internal business strategy, inventory control, and monthly or quarterly sales targets. In addition, sale location can also affect the final selling price of a device, both in terms of geographical region and facility type. Prices for the same medical device often vary in hospitals and health systems versus outside of hospital facilities, for example if high volume healthcare institutions can negotiate discounts or rebates based on large purchase sizes.
Tristate URSA overview
Tristate URSA LLC is a developer of angiographic catheter with unique polymer blend are designed to be used for delivering radiopaque media to the targeted sites in the vascular system. The company is headquartered in Glen Rock, New Jersey, the US.
For a complete picture of URSA, Cardiac Catheters pricing in the US, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.